Biotech Blueprint

Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs.

Subscribe to our newsletter on Substack: biotechblueprint.com.

Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build
Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build
Drug launch prices soar; mRNA shots linked to longer cancer survival — This Week in Biotech
Drug launch prices soar; mRNA shots linked to longer cancer survival — This Week in Biotech
How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer
How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer
Trump cuts IVF & Medicaid drug prices; Novo buys Omeros; Lilly's GLP-1 orforglipron shines
Trump cuts IVF & Medicaid drug prices; Novo buys Omeros; Lilly's GLP-1 orforglipron shines
Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech
Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech
ACIP votes, Roche-89bio deal, Regeneron’s FOP win — This Week in Biotech
ACIP votes, Roche-89bio deal, Regeneron’s FOP win — This Week in Biotech
The mRNA Revolution: Beyond COVID to Cancer, Flu and Herpes Vaccines
The mRNA Revolution: Beyond COVID to Cancer, Flu and Herpes Vaccines
Novo’s Layoffs, #Novartis’ $1.4B Buy, #Pancreatic #Cancer Progress — This Week in Biotech #news
Novo’s Layoffs, #Novartis’ $1.4B Buy, #Pancreatic #Cancer Progress — This Week in Biotech #news
Ionis' Olezarsen Win, #Novartis Licenses Arrowhead, #CDC #Vaccine Fight — This Week in Biotech #news
Ionis' Olezarsen Win, #Novartis Licenses Arrowhead, #CDC #Vaccine Fight — This Week in Biotech #news
Subscribe for free biotech & pharma newsletter
Subscribe for free biotech & pharma newsletter
Monarez Fired, Novo’s srRNA Deal, ImmunityBio Wows in GBM — This Week in Biotech #67
Monarez Fired, Novo’s srRNA Deal, ImmunityBio Wows in GBM — This Week in Biotech #67
Viking Falls on Obesity Pill, Rocket’s Therapy Resumes, FDA Approves Papzimeos —This Week in Biotech
Viking Falls on Obesity Pill, Rocket’s Therapy Resumes, FDA Approves Papzimeos —This Week in Biotech
Lilly Bets on #AI, #Prasad Returns, and Brinsupri Breaks Through - This Week in Biotech #news
Lilly Bets on #AI, #Prasad Returns, and Brinsupri Breaks Through - This Week in Biotech #news
#RFK Jr. Ends #mRNA Funding, #Sarepta Beats Q2, and Eli Lilly Falls — This Week in #Biotech #news
#RFK Jr. Ends #mRNA Funding, #Sarepta Beats Q2, and Eli Lilly Falls — This Week in #Biotech #news
#FDA Shake Up, #Sarepta Rebounds, and Trump Targets Drug Prices — This Week in #Biotech 63 #news
#FDA Shake Up, #Sarepta Rebounds, and Trump Targets Drug Prices — This Week in #Biotech 63 #news
Sarepta, Elevidys, and the Future of AAV Gene Therapy #podcast #biotechnology #news #genetherapy
Sarepta, Elevidys, and the Future of AAV Gene Therapy #podcast #biotechnology #news #genetherapy
#Sarepta’s Gene Therapy Crisis Deepens — This Week in Biotech 62 #news #science #pharma #biotech
#Sarepta’s Gene Therapy Crisis Deepens — This Week in Biotech 62 #news #science #pharma #biotech
#Sarepta’s $400M Pivot, MiNK’s 500% Surge, and AML Breakthroughs — This Week in #Biotech #news
#Sarepta’s $400M Pivot, MiNK’s 500% Surge, and AML Breakthroughs — This Week in #Biotech #news
CRISPR in 2025: Clinical Use, Regulatory Pressure, and Future Promise
CRISPR in 2025: Clinical Use, Regulatory Pressure, and Future Promise
KalVista’s FDA Win, Merck’s $10B Deal, and CRISPR Momentum — Biotech #60
KalVista’s FDA Win, Merck’s $10B Deal, and CRISPR Momentum — Biotech #60
Sparks Fly in Biotech — This Week in #Biotech edition 59
Sparks Fly in Biotech — This Week in #Biotech edition 59
FDA Drama & Psychedelic Setback — This Week in Biotech 58 #biotechnology #news #fda #pharma #science
FDA Drama & Psychedelic Setback — This Week in Biotech 58 #biotechnology #news #fda #pharma #science
HIV Breakthrough & Gene Editing Deals — This Week in Biotech #57
HIV Breakthrough & Gene Editing Deals — This Week in Biotech #57
Biotech Caught Between AI Momentum and Political Turbulence — This Week in Biotech #56
Biotech Caught Between AI Momentum and Political Turbulence — This Week in Biotech #56
Navigating Biotech Jobs in 2025: AI, Networking, and Career Strategy
Navigating Biotech Jobs in 2025: AI, Networking, and Career Strategy
ASCO Breakthroughs, Gene Therapy Stumbles, and Omada's IPO debut — This Week in Biotech #55
ASCO Breakthroughs, Gene Therapy Stumbles, and Omada's IPO debut — This Week in Biotech #55
CRISPR Setback, Vaccine Policy Reversed, and Oral Antibiotic Breakthrough — This Week in Biotech #54
CRISPR Setback, Vaccine Policy Reversed, and Oral Antibiotic Breakthrough — This Week in Biotech #54
Gene Editing Breakthroughs Explained! 🧬
Gene Editing Breakthroughs Explained! 🧬
Organoids, AI, and the FDA’s Move Away from Animal Models
Organoids, AI, and the FDA’s Move Away from Animal Models
Tighter Boosters, Novavax's Win, and Psychedelic Signals — This Week in Biotech #53
Tighter Boosters, Novavax's Win, and Psychedelic Signals — This Week in Biotech #53